MJA
MJA

Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin

Ange D Dossou, Ghislain E Sopoh, Christian R Johnson, Yves T Barogui, Dissou Affolabi, Sévérin Y Anagonou, Théophile Zohoun, Françoise Portaels and Kingsley Asiedu
Med J Aust 2008; 189 (9): . || doi: 10.5694/j.1326-5377.2008.tb02166.x
Published online: 3 November 2008

To the Editor: Buruli ulcer, caused by the bacterium Mycobacterium ulcerans, leads to the destruction of skin and sometimes bone. It has been reported in many tropical countries in Africa and in some temperate regions of Australia, Japan and China.1 In 2004, the World Health Organization recommended treatment with the combination of oral rifampicin and intramuscular streptomycin (or amikacin) for 8 weeks.2,3 In-vitro studies and new data from mouse models suggest that combinations of rifampicin with clarithromycin, rifampicin with moxifloxacin, or clarithromycin with moxifloxacin may be as effective as rifampicin and streptomycin.4,5

Online responses are no longer available. Please refer to our instructions for authors page for more information.